SENSITIVE GAS-LIQUID-CHROMATOGRAPHIC METHOD FOR THE DETERMINATION OF LORATADINE AND ITS MAJOR ACTIVE METABOLITE, DESCARBOETHOXYLORATADINE, IN HUMAN PLASMA USING A NITROGEN-PHOSPHORUS DETECTOR

被引:70
作者
JOHNSON, R
CHRISTENSEN, J
LIN, CC
机构
[1] SCHERING PLOUGH RES INST,KENILWORTH,NJ 07033
[2] WISCONSIN ANALYT & RES SERV,MADISON,WI 53713
来源
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS | 1994年 / 657卷 / 01期
关键词
D O I
10.1016/0378-4347(94)80078-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive gas-liquid chromatographic (GLC) method was developed for the determination of loratadine, a long-acting tricyclic antihistamine, and its active metabolite, descarboethoxyloratadine, in human plasma. The method involved extraction with organic solvent at neutral and alkaline pH. The organic layer from the neutral pH extraction was evaporated to dryness, reconstituted and injected into the GLC system. On the other hand, to the organic layer from the alkaline pH extraction trifluoroacetic anhydride was added. Following addition of H,O, the mixture was centrifuged and the organic layer was evaporated to dryness, reconstituted and injected onto the GLC system that was equipped with a nitrogen specific detector and a fused-silica capillary column. The linearity for both loratadine and descarboxyloratadine were demonstrated with r greater than or equal to 0.998 at concentrations ranging from 0.1 to 30 ng/ml. The results showed that the GLC method was accurate (bias less than or equal to 12%) and precise (coefficient of variation, C.V., less than or equal to 12%) for loratadine and descarboethoxyloratadine. The limit of quantitation was 0.1 ng/ml for loratadine with a C.V. of 9.2% and for descarboethoxyloratadine with a C.V. of 5.3%. The GLC method described has been demonstrated to be useful for the determination of loratadine and descarboethoxyloratadine in plasma samples of pediatric volunteers following oral administration of a single dose of 10 mg of loratadine syrup.
引用
收藏
页码:125 / 131
页数:7
相关论文
共 11 条
[1]   SELECTIVE DISPLACEMENT OF [H-3] MEPYRAMINE FROM PERIPHERAL VS CENTRAL-NERVOUS-SYSTEM RECEPTORS BY LORATADINE, A NONSEDATING ANTIHISTAMINE [J].
AHN, HS ;
BARNETT, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 127 (1-2) :153-155
[2]   EVALUATION OF THE CNS PROPERTIES OF SCH-29851, A POTENTIAL NON-SEDATING ANTIHISTAMINE [J].
BARNETT, A ;
IORIO, LC ;
KREUTNER, W ;
TOZZI, S ;
AHN, HS ;
GULBENKIAN, A .
AGENTS AND ACTIONS, 1984, 14 (5-6) :590-597
[3]   PHARMACOLOGICAL EVALUATION OF LORATADINE (SCH 29851), CHLORPHENIRAMINE AND PLACEBO [J].
BATENHORST, RL ;
BATENHORST, AS ;
GRAVES, DA ;
FOSTER, TS ;
KUNG, M ;
GURAL, RP ;
AMKRAUT, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :247-250
[4]   LORATADINE (SCH29851) 40 MG ONCE DAILY VERSUS TERFENADINE 60 MG TWICE DAILY IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS [J].
BRUTTMANN, G ;
PEDRALI, P .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1987, 15 (02) :63-70
[5]   PHARMACOKINETICS AND DOSE PROPORTIONALITY OF LORATADINE [J].
HILBERT, J ;
RADWANSKI, E ;
WEGLEIN, R ;
LUC, V ;
PERENTESIS, G ;
SYMCHOWICZ, S ;
ZAMPAGLIONE, N .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (09) :694-698
[6]  
KAMINSZCZIK I, 1986, ABSTR EUR ALL CL MAY
[7]  
KATCHEN B, 1985, ANN ALLERGY, V55, P366
[8]   ANTIALLERGIC ACTIVITY OF LORATADINE, A NONSEDATING ANTIHISTAMINE [J].
KREUTNER, W ;
CHAPMAN, RW ;
GULBENKIAN, A ;
SIEGEL, MI .
ALLERGY, 1987, 42 (01) :57-63
[9]   LORATADINE - MULTIPLE-DOSE PHARMACOKINETICS [J].
RADWANSKI, E ;
HILBERT, J ;
SYMCHOWICZ, S ;
ZAMPAGLIONE, N .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (07) :530-533
[10]  
VILLANI FJ, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1311